MedPath

Comparison in kshar sutra ligation & chedan karm in pilonidal sinus

Phase 1/2
Not yet recruiting
Conditions
Medical and Surgical. Ayurveda Condition: NADIVRANAH,
Registration Number
CTRI/2023/06/053996
Lead Sponsor
Sanjeet kumar sahu
Brief Summary

Kshar sutra is one of the best treatment mentioned by sushrut for the treatment of pilonidal sinus and here we are comparing it with chedan karm in pilonidal sinus. There is more reoocurance rate in chedan karm so i wanna prove that kshar sutra is much better treatment for pilonidal sinus. So that patients can get permanent relief.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria
  • The patients who presented with the signs & symptoms of Nadi Vrana W.S.R. to Pilonidal Sinus Sex.
  • Both Male & Female included in these clinical trials. Symptoms.
  • Pain, Swelling. Discharge and Discoloration Single Sinus track situated at midline of natal cleft. Patients willing to undergo clinical trial.
Exclusion Criteria
  • Patients aged below 18 and above 60 years of age Patients who are sensitive to Xylocaine will be excluded Pilonidal sinus more than 6 cm in length Lateral opening and Multiple sinus Systemic diseases like Diabetic mellitus, tuberculosis will be excluded.
  • Malignant condition Patients unfit for Surgical excision and Ksharasutra Ligation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Kshar sutra is better then chedan karma3 month
Secondary Outcome Measures
NameTimeMethod
Chedan karam takes less but has more reoccurance rate then kshar sutra or not3 month

Trial Locations

Locations (1)

Vaidya yagya dutt sharma ayurved maha vidyalaya, khurja ,bulandshahr, UP

🇮🇳

Bulandshahar, UTTAR PRADESH, India

Vaidya yagya dutt sharma ayurved maha vidyalaya, khurja ,bulandshahr, UP
🇮🇳Bulandshahar, UTTAR PRADESH, India
Sanjeet kumar sahu
Principal investigator
8960580421
drsanjeetsahu621@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.